Investigating IL-27 as a new treatment for cancer
IL-27 as a potential immunotherapeutic for cancer
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10640105
This study is looking at how a substance called IL-27 might help boost the immune system to fight cancer, especially for patients who haven't had success with other treatments, by using new methods to deliver it directly to the tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10640105 on ClinicalTrials.gov |
What this research studies
This research explores the potential of IL-27, a cytokine, as an immunotherapeutic agent for cancer treatment. It aims to understand how IL-27 can enhance the immune response against tumors, particularly in patients who do not respond to existing immunotherapies. The study will utilize advanced gene delivery methods to effectively administer IL-27 and assess its impact on tumor growth and immune cell activity. By focusing on the tumor microenvironment, the research seeks to identify ways to overcome resistance to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers who have not responded to traditional immunotherapies.
Not a fit: Patients with early-stage cancers or those who are already responding well to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with advanced cancer who currently have limited therapeutic choices.
How similar studies have performed: Other research has shown promise in using immunotherapeutic approaches similar to IL-27, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BASU, SUJIT — OHIO STATE UNIVERSITY
- Study coordinator: BASU, SUJIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease, Cancers, neoplasm/cancer